BACKGROUND: Clinical practice recommendations for hypertension do not make recommendations specific to men or women. However, the sex hormones appear to modulate differently the renin-angiotensin system (RAS), which plays a central role in the regulation of blood pressure. Today, little is known about the effects of sex on the efficacy of therapies that antagonize the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). OBJECTIVE: To identify randomized controlled trials evaluating the efficacy of ACEIs and ARBs in preventing major cardiovascular outcomes, determine what proportion of the trial participants were female, and evaluate whether there was any evidence of a sex difference in the efficacy of these agents. METHODS: A systematic review of the literature was conducted to identify randomized controlled trials that used either ACEIs or ARBs for the treatment of hypertension. RESULTS: Thirteen ACEI trials and nine ARB trials were identified. Sex-specific outcome data were available in six of the ACEI trials and three of the ARB trials. These trials enrolled 74,105 patients; 39.1% were women. Seven of the nine trials indicated that ACEIs or ARBs may be slightly more beneficial in men. The magnitude of these differences, in most trials, was small. CONCLUSIONS: Sex-specific data are reported in 43% of large hypertension clinical trials. Review of the trials reporting sex-specific effect sizes indicates that ACEIs and ARBs may be more effective in men.
BACKGROUND: Clinical practice recommendations for hypertension do not make recommendations specific to men or women. However, the sex hormones appear to modulate differently the renin-angiotensin system (RAS), which plays a central role in the regulation of blood pressure. Today, little is known about the effects of sex on the efficacy of therapies that antagonize the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). OBJECTIVE: To identify randomized controlled trials evaluating the efficacy of ACEIs and ARBs in preventing major cardiovascular outcomes, determine what proportion of the trial participants were female, and evaluate whether there was any evidence of a sex difference in the efficacy of these agents. METHODS: A systematic review of the literature was conducted to identify randomized controlled trials that used either ACEIs or ARBs for the treatment of hypertension. RESULTS: Thirteen ACEI trials and nine ARB trials were identified. Sex-specific outcome data were available in six of the ACEI trials and three of the ARB trials. These trials enrolled 74,105 patients; 39.1% were women. Seven of the nine trials indicated that ACEIs or ARBs may be slightly more beneficial in men. The magnitude of these differences, in most trials, was small. CONCLUSIONS: Sex-specific data are reported in 43% of large hypertension clinical trials. Review of the trials reporting sex-specific effect sizes indicates that ACEIs and ARBs may be more effective in men.
Authors: Judith A Miller; David Z Cherney; John A Duncan; Vesta Lai; Kevin D Burns; Christopher R J Kennedy; Joseph Zimpelmann; Wei Gao; Daniel C Cattran; James W Scholey Journal: J Am Soc Nephrol Date: 2006-08-16 Impact factor: 10.121
Authors: Alberto Zanchetti; Stevo Julius; Sverre Kjeldsen; Gordon T McInnes; Tsushung Hua; Michael Weber; John H Laragh; Francis Plat; Edouard Battegay; Cesar Calvo-Vargas; Andrzej Cieśliński; Jean Paul Degaute; Nicolaas J Holwerda; Janna Kobalava; Ole Lederballe Pedersen; Faustinus P Rudyatmoko; Kostas C Siamopoulos; Oyvind Störset Journal: J Hypertens Date: 2006-11 Impact factor: 4.844
Authors: Peter Trenkwalder; Dag Elmfeldt; Albert Hofman; Hans Lithell; Bertil Olofsson; Vasilios Papademetriou; Ingmar Skoog; Alberto Zanchetti Journal: Blood Press Date: 2005 Impact factor: 2.835
Authors: Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener Journal: Stroke Date: 2005-05-05 Impact factor: 7.914
Authors: Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen Journal: N Engl J Med Date: 2004-10-31 Impact factor: 91.245
Authors: Kimberley M Mellor; Claire L Curl; Chanchal Chandramouli; Thierry Pedrazzini; Igor R Wendt; Lea M D Delbridge Journal: Age (Dordr) Date: 2014-02-25
Authors: Stephanie M Toth-Manikowski; Wei Yang; Lawrence Appel; Jing Chen; Rajat Deo; Anne Frydrych; Marie Krousel-Wood; Mahboob Rahman; Sylvia E Rosas; Daohang Sha; Jackson Wright; Martha L Daviglus; Alan S Go; James P Lash; Ana C Ricardo Journal: Am J Kidney Dis Date: 2021-04-20 Impact factor: 11.072
Authors: Marion Doull; Vivian Welch; Lorri Puil; Vivien Runnels; Stephanie E Coen; Beverley Shea; Jennifer O'Neill; Cornelia Borkhoff; Sari Tudiver; Madeline Boscoe Journal: PLoS One Date: 2014-11-05 Impact factor: 3.240
Authors: Sanjay Ranjit; Jian Yao Wong; Jia W Tan; Chee Sin Tay; Jessica M Lee; Kelly Yin Han Wong; Luminita H Pojoga; Danielle L Brooks; Amanda E Garza; Stephen A Maris; Isis Akemi Katayama; Jonathan S Williams; Alicia Rivera; Gail K Adler; Gordon H Williams; Jose R Romero Journal: JCI Insight Date: 2019-11-01